DK0691966T3 - Quinoliner som type IV phosphodiesteraseinhibitorer - Google Patents
Quinoliner som type IV phosphodiesteraseinhibitorerInfo
- Publication number
- DK0691966T3 DK0691966T3 DK94911662T DK94911662T DK0691966T3 DK 0691966 T3 DK0691966 T3 DK 0691966T3 DK 94911662 T DK94911662 T DK 94911662T DK 94911662 T DK94911662 T DK 94911662T DK 0691966 T3 DK0691966 T3 DK 0691966T3
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- quinolines
- type
- phosphodiesterase inhibitors
- arylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/040,731 US5455252A (en) | 1993-03-31 | 1993-03-31 | Optionally substituted 6,8-quinolines |
| PCT/US1994/003004 WO1994022852A1 (en) | 1993-03-31 | 1994-03-23 | Quinolines as type iv phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0691966T3 true DK0691966T3 (da) | 1999-02-08 |
Family
ID=21912628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94911662T DK0691966T3 (da) | 1993-03-31 | 1994-03-23 | Quinoliner som type IV phosphodiesteraseinhibitorer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5455252A (de) |
| EP (1) | EP0691966B1 (de) |
| JP (1) | JP3564133B2 (de) |
| KR (1) | KR100300275B1 (de) |
| AT (1) | ATE170855T1 (de) |
| AU (1) | AU679222B2 (de) |
| DE (1) | DE69413215T2 (de) |
| DK (1) | DK0691966T3 (de) |
| ES (1) | ES2120028T3 (de) |
| FI (1) | FI109692B (de) |
| HU (2) | HUT73181A (de) |
| NO (1) | NO305282B1 (de) |
| NZ (1) | NZ263436A (de) |
| WO (1) | WO1994022852A1 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523267D0 (en) * | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| CZ296163B6 (cs) * | 1996-05-20 | 2006-01-11 | Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV | |
| AU722662B2 (en) * | 1996-05-20 | 2000-08-10 | Darwin Discovery Limited | Quinoline sulfonamides as TNF inhibitors and as PDE-IV inhibitors |
| JP4373497B2 (ja) | 1996-06-19 | 2009-11-25 | ローン−プーラン・ロレ・リミテツド | 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用 |
| US6069151A (en) * | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
| GB9712761D0 (en) * | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| IT1302677B1 (it) * | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| ES2241571T3 (es) * | 1999-01-15 | 2005-11-01 | Altana Pharma Ag | N-oxidos de fenantrinida con actividad inhividora de pde-iv. |
| DE60020079T2 (de) * | 1999-01-15 | 2006-01-19 | Altana Pharma Ag | Phenanthridin-N-oxide mit PDE-IV-hemmender Wirkung |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| MY134008A (en) * | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
| US6639077B2 (en) | 2000-03-23 | 2003-10-28 | Merck Frosst Canada & Co. | Tri-aryl-substituted-ethane PDE4 inhibitors |
| MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
| EP1289961A1 (de) | 2000-05-25 | 2003-03-12 | Merck Frosst Canada & Co. | Fluoroalkoxy-substituiertes benzamid-dichloropyridinyl-n-oxid als pde4 inhibitor |
| US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| EP1389468A4 (de) | 2001-05-23 | 2007-01-10 | Tanabe Seiyaku Co | Zusammensetzungen zur förderung der knochenfrakturheilung |
| CN1537018A (zh) | 2001-05-23 | 2004-10-13 | 田边制药株式会社 | 一种用于软骨疾病再生治疗的组合物 |
| CA2447765C (en) | 2001-05-24 | 2011-01-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| WO2003002118A1 (en) * | 2001-06-27 | 2003-01-09 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline pde4 inhibitors |
| JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| EP1487797B1 (de) | 2002-03-18 | 2009-05-27 | Merck Frosst Canada Ltd. | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
| ATE356808T1 (de) * | 2002-06-25 | 2007-04-15 | Merck Frosst Canada Ltd | 8-(biaryl)chinolin-pde4-inhibitoren |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US7153824B2 (en) | 2003-04-01 | 2006-12-26 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
| CA2523336A1 (en) | 2003-04-30 | 2004-11-11 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors |
| EP2275095A3 (de) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (de) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| EP2066653B1 (de) | 2006-08-03 | 2012-09-12 | Rottapharm S.p.A. | 6-1h-imidazochinazolin- und chinolinderivate, neue wirksame analgetika und entzündungshemmende mittel |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| MX2010014394A (es) | 2008-06-20 | 2011-05-19 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina. |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2796826A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| UY33373A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?. |
| EP2602254B1 (de) * | 2010-08-04 | 2017-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| DK2681236T3 (en) | 2011-03-01 | 2018-04-16 | Synergy Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| CA3006683A1 (en) | 2015-12-22 | 2017-06-29 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
| EP4706758A3 (de) | 2019-05-21 | 2026-05-06 | Ardelyx, Inc. | Verfahren zur hemmung des phosphattransports |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563460A (en) * | 1984-01-13 | 1986-01-07 | William H. Rorer, Inc. | Quinoline and quinazoline derivatives for treating gastrointestinal motility dysfunctions |
| US4672029A (en) * | 1984-12-06 | 1987-06-09 | Eastman Kodak Company | Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes |
| CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| DE3935491A1 (de) * | 1989-10-25 | 1991-05-02 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe |
-
1993
- 1993-03-31 US US08/040,731 patent/US5455252A/en not_active Expired - Lifetime
-
1994
- 1994-03-23 HU HU9502845A patent/HUT73181A/hu not_active Application Discontinuation
- 1994-03-23 AT AT94911662T patent/ATE170855T1/de not_active IP Right Cessation
- 1994-03-23 DE DE69413215T patent/DE69413215T2/de not_active Expired - Fee Related
- 1994-03-23 NZ NZ263436A patent/NZ263436A/xx unknown
- 1994-03-23 AU AU64129/94A patent/AU679222B2/en not_active Ceased
- 1994-03-23 WO PCT/US1994/003004 patent/WO1994022852A1/en not_active Ceased
- 1994-03-23 EP EP94911662A patent/EP0691966B1/de not_active Expired - Lifetime
- 1994-03-23 DK DK94911662T patent/DK0691966T3/da active
- 1994-03-23 KR KR1019950704211A patent/KR100300275B1/ko not_active Expired - Fee Related
- 1994-03-23 ES ES94911662T patent/ES2120028T3/es not_active Expired - Lifetime
- 1994-03-23 JP JP52213694A patent/JP3564133B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-24 HU HU95P/P00111P patent/HU210816A9/hu unknown
- 1995-09-29 NO NO953879A patent/NO305282B1/no not_active IP Right Cessation
- 1995-09-29 FI FI954651A patent/FI109692B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ263436A (en) | 1997-08-22 |
| FI954651A7 (fi) | 1995-09-29 |
| NO953879D0 (no) | 1995-09-29 |
| ATE170855T1 (de) | 1998-09-15 |
| HU9502845D0 (en) | 1995-11-28 |
| WO1994022852A1 (en) | 1994-10-13 |
| ES2120028T3 (es) | 1998-10-16 |
| NO305282B1 (no) | 1999-05-03 |
| DE69413215T2 (de) | 1999-01-28 |
| HUT73181A (en) | 1996-06-28 |
| EP0691966A1 (de) | 1996-01-17 |
| HU210816A9 (en) | 1995-08-28 |
| NO953879L (no) | 1995-11-22 |
| FI954651A0 (fi) | 1995-09-29 |
| EP0691966B1 (de) | 1998-09-09 |
| FI109692B (fi) | 2002-09-30 |
| KR100300275B1 (ko) | 2001-10-22 |
| JPH08511238A (ja) | 1996-11-26 |
| AU679222B2 (en) | 1997-06-26 |
| DE69413215D1 (en) | 1998-10-15 |
| JP3564133B2 (ja) | 2004-09-08 |
| AU6412994A (en) | 1994-10-24 |
| US5455252A (en) | 1995-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0691966T3 (da) | Quinoliner som type IV phosphodiesteraseinhibitorer | |
| TR200002618T2 (tr) | Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi | |
| MX9606203A (es) | Derivados heterociclicos sustituidos. | |
| AU7585598A (en) | Raf kinase inhibitors | |
| AP1246A (en) | Substituted pyrazoles as p38 Kinase inhibitors. | |
| CA2339630A1 (en) | Carboline derivatives as cgmp phosphodiesterase inhibitors | |
| NO20005994D0 (no) | Nye dipeptidylpeptidase IV effektorer | |
| YU35601A (sh) | SUPSTITUISANI PIRAZOLI KAO INHIBITORI p38 KINAZE | |
| PT1056725E (pt) | Inibicao da raf-quinase usando ureias heterociclicas substituidas com arilo e heteroarilo | |
| IL114315A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV | |
| NZ326331A (en) | Heterocycle-condensed morphinoid derivatives and medicaments | |
| PL328323A1 (en) | Novel indolic and indazolic compounds, method of obtaining them and pharmaceutic preparations containing such compounds | |
| MXPA03007261A (es) | Moduladores del receptor de glucocorticoides. | |
| CA2307581A1 (en) | Heterocyclic compounds having nos inhibiting action | |
| CA2273328A1 (en) | 5-cyclo indole compounds as 5-ht1d receptor ligands | |
| ATE318600T1 (de) | Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel | |
| NZ306204A (en) | N-hydrocarbyl-benzamide derivatives substituted by acetamido, nitro, or amino | |
| MXPA03000887A (es) | Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa. | |
| GB2360785B (en) | Porphyrins and related compounds | |
| NO980654D0 (no) | Fremgangsmåte for bekjempelse av fiskemykoser og encellete ektoparasitter | |
| TW338039B (en) | Salts of inidazoline derivatives | |
| EP1121338A4 (de) | Eine methode zur herstellung von diaryl-substituierten heterocyclischen verbindungen, einschliesslich tetrahydrofurane | |
| MX9707187A (es) | Derivados de imidazopiridina. | |
| FI956238A7 (fi) | Lantanidien kompleksiyhdisteet, jotka sisältävät heterosyklisiä karbeeneja | |
| AU2666200A (en) | Substituted pyrazole benzyl amine derivatives to combat anaemias |